Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263640
Status:
COMPLETED
Last Update Posted:
2015-01-15
First Post:
2005-12-08
Brief Title:
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
Sponsor:
Allergopharma GmbH Co KG
Organization:
Allergopharma GmbH Co KG
Study Overview
Official Title:
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum-Adsorbed Allergoid Preparation of House Dust Mite D Pteronyssinus in Patients With Allergic Bronchial Asthma Rhinitis Rhinoconjunctivitis
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma
Detailed Description:
The rationale for the present study was to demonstrate clinical efficacy and tolerability compared to placebo in a phase III clinical study of pivotal character with a representative number of patients suffering from fully reversible asthma - allergic rhinitis This condition is present in paediatric and adult patients with a shorter history of GINA II and III asthma who were investigated in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-003892-35 | EUDRACT_NUMBER | None | None |